Extensive experimental evidence shows that platelets support tumour metastasis. The activation of platelets and the coagulation system have a crucial role in the progression of cancer. Within the circulatory system, platelets guard tumour cells from immune elimination and promote their arrest at the endothelium, supporting the establishment of secondary lesions. These contributions of platelets to tumour cell survival and spread suggest platelets as a new avenue for therapy.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Signal Transduction and Targeted Therapy Open Access 07 August 2023
Molecular Cancer Open Access 18 April 2023
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis
Journal of Experimental & Clinical Cancer Research Open Access 22 March 2023
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Khorana, A. A. & Connolly, G. C. Assessing risk of venous thromboembolism in the patient with cancer. J. Clin. Oncol. 27, 4839–4847 (2009).
Lyman, G. H. & Khorana, A. A. Cancer, clots and consensus: new understanding of an old problem. J. Clin. Oncol. 27, 4821–4826 (2009).
Khorana, A. A. & Fine, R. L. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 5, 655–663 (2004).
Lugassy, G., Falanga, A., Kakkar, A. & Rickles, F. Thrombosis and Cancer (Informa Health Care, London, 2004).
Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nature Rev. Cancer 9, 239–252 (2009).
Trousseau, A. in Clinique Medicale de l'Hotel-Dieu de Paris 2nd ed (ed. Bailliere, J. B. ) Vol. 3, 654–712 (Paris,1865).
Khorana, A. A. Malignancy, thrombosis and Trousseau: the case for an eponym. J. Thromb. Haemost. 1, 2463–2465 (2003).
Sierko, E. & Wojtukiewicz, M. Z. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin. Thromb. Hemost. 33, 712–721 (2007).
Sierko, E. & Wojtukiewicz, M. Z. Platelets and angiogenesis in malignancy. Semin. Thromb. Hemost. 30, 95–108 (2004).
Prisco, D. et al. Platelet activation and platelet lipid composition in pulmonary cancer Prostaglandins Leukot. Essent. Fatty Acids 53, 65–68 (1995).
Blann, A. D. et al. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul. Fibrinolysis 12, 43–50 (2001).
Verheul, H. M. W. et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin. Cancer Res. 6, 166–171 (2000).
Erdemir, F. et al. Clinical significance of platelet count in patients with renal cell carcinoma. Urol. Int. 79, 111–116 (2007).
Costantini, V., Zacharski, L. R., Moritz, T. E. & Edwards, R. L. The platelet count in carcinoma of the lung and colon. Thromb. Haemost. 64, 501–505 (1990).
Ayhan, A. et al. The value of preoperative platelet count in the prediction of cervical involvement and poor prognostic variables in patients with endometrial carcinoma. Gynecol. Oncol. 103, 902–905 (2006).
Taucher, S. et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb. Haemost. 89, 1098–1106 (2003).
Brown, K. M., Domin, C., Aranha, G. V., Yong, S. & Shoup, M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am. J. Surg. 189, 278–282 (2005).
Bensalah, K. et al. Prognostic value of thrombocytosis in renal cell carcinoma. J. Urol. 175, 859–863 (2006).
Brockmann, M. A. et al. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-Oncology 9, 335–342 (2007).
Kaushansky, K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 111, 981–986 (2008).
Ruggeri, Z. M. & Mendolicchio, G. L. Adhesion mechanisms in platelet function. Circ. Res. 100, 1673–1685 (2007).
Davi, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482–2494 (2007).
Kakkar, A. K., Deruvo, N., Chinswangwatanakul, V., Tebbutt, S. & Williamson, R. C. N. Extrinsic-pathway activation in cancer with high factor VIIA and tissue factor. Lancet 346, 1004–1005 (1995).
Mueller, B. M., Reisfeld, R. A., Edgington, T. S. & Ruf, W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc. Natl Acad. Sci. USA 89, 11832–11836 (1992).
Ruf, W. & Mueller, B. M. Thrombin generation and the pathogenesis of cancer. Semin. Thromb. Hemost. 32, 061, 068 (2006).
Esumi, N., Fan, D. & Fidler, I. J. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 51, 4549–4556 (1991).
Nierodzik, M. L., Plotkin, A., Kajumo, F. & Karpatkin, S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J. Clin. Invest. 87, 229–236 (1991).
Hu, L., Lee, M., Campbell, W., Perez-Soler, R. & Karpatkin, S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104, 2746–2751 (2004).
Nierodzik, M. L. & Karpatkin, S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10, 355–362 (2006).
Ruf, W. Tissue factor and PAR signaling in tumor progression. Thromb. Res. 120, S7–S12 (2007).
Ruf, W., Yokota, N. & Schaffner, F. Tissue factor in cancer progression and angiogenesis. Thromb. Res. 125, S36–S38 (2010).
Gupta, G. P. & Massague, J. Cancer metastasis: Building a framework. Cell 127, 679–695 (2006).
Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nature Rev. Cancer 9, 274–284 (2009).
Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nature Rev. Cancer 9, 285–293 (2009).
Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nature Med. 12, 895–904 (2006).
Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563–572 (2002).
Honn, K. V., Tang, D. G. & Chen, Y. Q. Platelets and cancer metastasis-more than an epiphenomenon. Semin. Thromb. Hemost. 18, 392–415 (1992).
Mehta, P. Potential role of platelets in the pathogenesis of tumor-metastasis. Blood 63, 55–63 (1984).
Jurasz, P., Alonso-Escolano, D. & Radomski, M. W. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 143, 819–826 (2004).
Erpenbeck, L. & Schon, M. P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 115, 3427–3436 (2010).
Folkman, J. et al. Tumor angiogenesis-therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Mohle, R., Green, D., Moore, M., Nachman, R. & Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl Acad. Sci. USA 94, 663–668 (1997).
Pinedo, H. M., Verheul, H. M. W., D'Amato, R. J. & Folkman, J. Involvement of platelets in tumour angiogenesis? The Lancet 352, 1775–1777 (1998).
Coppinger, J. A. et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103, 2096–2104 (2004).
Smyth, S. S. et al. Platelet functions beyond hemostasis. J. Thromb. Haemost. 7, 1759–1766 (2009).
Brock, T. A., Dvorak, H. F. & Senger, D. R. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am. J. Pathol. 138, 213–221 (1991).
Jin, D. K. et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nature Med. 12, 557–567 (2006).
Ma, L. et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl Acad. Sci. USA 102, 216–220 (2005).
Italiano, J. E. Jr et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released. Blood 111, 1227–1233 (2008).
Boucharaba, A. et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114, 1714–1725 (2004).
Kim, Y. J., Borsig, L., Varki, N. M. & Varki, A. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl Acad. Sci. USA 95, 9325–9330 (1998).
Zaslavsky, A. et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115, 4605–4613 (2010).
Palumbo, J. S. et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105, 178–185 (2005).
Palumbo, J. S. et al. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 62, 6966–6972 (2002).
Jain, S., Russell, S. & Ware, J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J. Thromb. Haemost. 7, 1713–1717 (2009).
Ho-Tin-Noe, B., Goerge, T., Cifuni, S. M., Duerschmied, D. & Wagner, D. D. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 68, 6851–6858 (2008).
Ho-Tin-Noe, B. et al. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am. J. Pathol. 175, 1699–1708 (2009).
Ho-Tin-Noe, B., Goerge, T. & Wagner, D. D. Platelets: guardians of tumor vasculature. Cancer Res. 69, 5623–5626 (2009).
Kisucka, J. et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl Acad. Sci. USA 103, 855–860 (2006).
Manegold, P. C., Hutter, J., Pahernik, S. A., Messmer, K. & Dellian, M. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood 101, 1970–1976 (2003).
Gasic, G. J., Gasic, T. B. & Stewart, C. C. Antimetastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 61, 46–52 (1968).
Camerer, E. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104, 397–401 (2004).
Karpatkin, S., Pearlstein, E., Ambrogio, C. & Coller, B. S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis in vivo. J. Clin. Invest. 81, 1012–1019 (1988).
Sambrano, G. R., Weiss, E. J., Zheng, Y.-W., Huang, W. & Coughlin, S. R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413, 74–78 (2001).
Palumbo, J. S. et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96, 3302–3309 (2000).
Versteeg, H. H. et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 68, 7219–7227 (2008).
Hu, L., Roth, J. M., Brooks, P., Ibrahim, S. & Karpatkin, S. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res. 68, 4296–4302 (2008).
Jones, D. S., Wallace, A. C. & Fraser, E. E. Sequence of events in experimental metastases of walker 256 tumor-light, immunofluorescent, and electron microscopic observations. J. Natl. Cancer Inst. 46, 493-& (1971).
Crissman, J. D., Hatfield, J., Schaldenbrand, M., Sloane, B. F. & Honn, K. V. Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Lab. Invest. 53, 470–478 (1985).
Sindelar, W. F., Tralka, T. S. & Ketcham, A. S. Electron microscopic observations on formation of pulmonary metastases. J. Surg. Res. 18, 137–161 (1975).
Borsig, L. et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA 98, 3352–3357 (2001).
Nieswandt, B., Hafner, M., Echtenacher, B. & Mannel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59, 1295–1300 (1999).
Malik, G. et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res. 70, 4327–4334 (2010).
Palumbo, J. S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin. Thromb. Hemost. 34, 154–160 (2008).
Palumbo, J. S. et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110, 133–141 (2007).
Wenzel, J., Zeisig, R. & Fichtner, I. Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions. Clin. Exp. Metastasis 27, 25–34 (2010).
Offermanns, S., Toombs, C. F., Hu, Y.-H. & Simon, M. I. Defective platelet activation in G-α-q-deficient mice. Nature 389, 183–186 (1997).
Palumbo, J. S. & Degen, J. L. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb. Res. 120, S22–S28 (2007).
Kopp, H. G., Placke, T. & Salih, H. R. Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69, 7775–7783 (2009).
Im, J. H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 64, 8613–8619 (2004).
Läubli, H. & Borsig, L. Selectins promote tumor metastasis. Semin. Cancer Biol. 20, 169–177 (2010).
Konstantopoulos, K. & Thomas, S. N. Cancer cells in transit: the vascular interactions of tumor cells. Annu. Rev. Biomed. Eng. 11, 177–202 (2009).
Kim, Y. J., Borsig, L., Han, H. L., Varki, N. M. & Varki, A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am. J. Pathol. 155, 461–472 (1999).
Ludwig, R. J. et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 64, 2743–2750 (2004).
Mousa, S. A. & Petersen, L. J. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb. Haemost. 102, 258–267 (2009).
Varki, A. P., Varki, N. M. & Borsig, L. Selectins, heparins, and cancer: rationale for clinical trials. Blood 112, 1348–1348 (2008).
Borsig, L., Wong, R., Hynes, R. O., Varki, N. M. & Varki, A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl Acad. Sci. USA 99, 2193–2198 (2002).
Laubli, H., Spanaus, K. S. & Borsig, L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 114, 4583–4591 (2009).
Alves, C. S., Burdick, M. M., Thomas, S. N., Pawar, P. & Konstantopoulos, K. The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. Am. J. Physiol. Cell Physiol. 294, C907–C916 (2008).
McCarty, O. J. T., Mousa, S. A., Bray, P. F. & Konstantopoulos, K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 96, 1789–1797 (2000).
Shattil, S. J., Kim, C. & Ginsberg, M. H. The final steps of integrin activation: the end game. Nature Rev. Mol. Cell Biol. 11, 288–300 (2010).
Felding-Habermann, B., Habermann, R., Saldivar, E. & Ruggeri, Z. M. Role of β3 integrins in melanoma cell adhesion to activated platelets under flow. J. Biol. Chem. 271, 5892–5900 (1996).
Amirkhosravi, A. et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb. Haemost. 90, 549–554 (2003).
Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nature Rev. Cancer 10, 9–22 (2010).
Bakewell, S. J. et al. Platelet and osteoclast β3 integrins are critical for bone metastasis. Proc. Natl Acad. Sci. USA 100, 14205–14210 (2003).
Gupta, G. P. & Massague, J. Platelets and metastasis revisited: a novel fatty link. J. Clin. Invest. 114, 1691–1693 (2004).
Arnaout, M. A., Mahalingam, B. & Xiong, J.-P. Integrin structure, allostery, and bidirectional signaling. Annu. Rev. Cell Dev. Biol. 21, 381–410 (2005).
Rose, D. M., Alon, R. & Ginsberg, M. H. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol. Rev. 218, 126–134 (2007).
Alcaide, P., Auerbach, S. & Luscinskas, F. W. Neutrophil recruitment under shear flow: it's all about endothelial cell rings and gaps. Microcirculation 16, 43–57 (2009).
Zarbock, A. & Ley, K. Mechanisms and consequences of neutrophil interaction with the endothelium. Am. J. Pathol. 172, 1–7 (2008).
Barthel, S. R., Johansson, M. W., McNamee, D. M. & Mosher, D. F. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J. Leukoc. Biol. 83, 1–12 (2008).
Hyduk, S. J. & Cybulsky, M. I. Role of α4β1 integrins in chemokine-induced monocyte arrest under conditions of shear stress. Microcirculation 16, 17–30 (2009).
Felding-Habermann, B. et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl Acad. Sci. USA 98, 1853–1858 (2001).
Rolli, M., Fransvea, E., Pilch, J., Saven, A. & Felding-Habermann, B. Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 9482–9487 (2003).
Felding-Habermann, B. Targeting tumor cell-platelet interaction in breast cancer metastasis. Pathophysiol. Haemost. Thromb. 33, 56–58 (2003).
Deryugina, E. & Quigley, J. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9–34 (2006).
Lorger, M., Krueger, J. S., O'Neal, M., Staflin, K. & Felding-Habermann, B. Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain. Proc. Natl Acad. Sci. USA 106, 10666–10671 (2009).
Felding-Habermann, B. et al. Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc. Natl Acad. Sci. USA 101, 17210–17215 (2004).
Staflin, K. et al. Targeting activated integrin αvβ3 with patient-derived antibodies impacts late-stage multiorgan metastasis. Clin. Exp. Metastasis 27, 217–231 (2010).
Taverna, D., Crowley, D., Connolly, M., Bronson, R. T. & Hynes, R. O. A direct test of potential roles for β3 and β5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res. 65, 10324–10329 (2005).
Morimoto, K. et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 27, 264–273 (2007).
Jain, S. et al. Platelet glycoprotein Ibα supports experimental lung metastasis. Proc. Natl Acad. Sci. USA 104, 9024–9028 (2007).
Kitagawa, H. et al. Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells. Cancer Res. 49, 537–541 (1989).
Erpenbeck, L., Nieswandt, B., Schon, M., Pozgajova, M. & Schon, M. P. Inhibition of platelet GPIbα and promotion of melanoma metastasis. J. Invest. Dermatol. 130, 576–586 (2009).
Terraube, V. et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J. Thromb. Haemost. 4, 519–526 (2006).
Terraube, V., Marx, I. & Denis, C. V. Role of von Willebrand factor in tumor metastasis. Thromb. Res. 120, S64–S70 (2007).
Marsolais, D. & Rosen, H. Chemical modulators of sphingosine 1 -phosphate receptors as barrier-oriented therapeutic molecules. Nature Rev. Drug Discov. 8, 297–307 (2009).
Yatomi, Y. et al. Sphingosine 1 -phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96, 3431–3438 (2000).
Schaphorst, K. L. et al. Role of sphingosine 1 -phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L258–L267 (2003).
Yin, F. & Watsky, M. A. LPA and S1P increase corneal epithelial and endothelial cell transcellular resistance. Invest. Ophthalmol. Vis. Sci. 46, 1927–1933 (2005).
Sarker, M. H., Hu, D. E. & Fraser, P. A. Regulation of cerebromicrovascular permeability by lysophosphatidic acid. Microcirculation 17, 39–46 (2010).
Côté, F., Fligny, C., Fromes, Y., Mallet, J. & Vodjdani, G. Recent advances in understanding serotonin regulation of cardiovascular function. Trend in Mol. Med. 10, 232–238 (2004).
Skolnik, G., Bagge, U., Dhlstrom, A. & Ahlman, H. The importance of 5-HT for tumor cell lodgement in the liver. Int. J. Cancer 33, 519–523 (1984).
Skolnik, G., Bagge, U., Blomqvist, G., Djarv, L. & Ahlman, H. The role of calcium channels and serotonin (5-HT2) receptors for tumour cell lodegment in the liver. Clin. Exp. Metastasis 7, 169–174 (1989).
Kuna, P. et al. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J. Immunol. 149, 636–642 (1992).
Lyman, G. H. et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490–5505 (2007).
Varki, A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110, 1723–1729 (2007).
Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A. J. & Morgan, G. Aspirin, salicylates, and cancer. The Lancet 373, 1301–1309 (2009).
Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008).
Verheul, H. M. W. et al. Platelets take up the monoclonal antibody bevacizumab. Clin. Cancer Res. 13, 5341–5347 (2007).
Kanter, J., Khan, S. Y., Kelher, M., Gore, L. & Silliman, C. C. Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates. Clin. Cancer Res. 14, 3942–3947 (2008).
Foss, B. & Bruserud, O. Platelet functions and clinical effects in acute myelogenous leukemia. Thromb. Haemost. 99, 27–37 (2008).
Cervi, D. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111, 1201–1207 (2008).
Klement, G. L. et al. Platelets actively sequester angiogenesis regulators. Blood 113, 2835–2842 (2009).
Borsig, L. The role of platelet activation in tumor metastasis. Expert Rev. Anticancer Ther. 8, 1247–1255 (2008).
Fang, J. et al. Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia. Blood 106, 2671–2679 (2005).
Freyssinet, J.-M. & Toti, F. Formation of procoagulant microparticles and properties. Thromb. Res. 125, S46–S48 (2010).
Muralidharan-Chari, V., Clancy, J. W., Sedgwick, A. & D'Souza-Schorey, C. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 123, 1603–1611 (2010).
Castellana, D., Toti, F. & Freyssinet, J. M. Membrane microvesicles: macromessengers in cancer disease and progression. Thromb. Res. 125, S84–S88 (2010).
Baj-Krzyworzeka, M. et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp. Hematol. 30, 450–459 (2002).
Janowska-Wieczorek, A., Marquez-Curtis, L. A., Wysoczynski, M. & Ratajczak, M. Z. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion (Paris). 46, 1199–1209 (2006).
Janowska-Wieczorek, A. et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113, 752–760 (2005).
Dashevsky, O., Varon, D. & Brill, A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int. J. Cancer 124, 1773–1777 (2009).
Kalinkovich, A. et al. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res. 66, 11013–11020 (2006).
Kim, H. K. et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur. J. Cancer 39, 184–191 (2003).
Helley, D. et al. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur. Urol. 56, 479–484 (2009).
Hron, G. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb. Haemost. 97, 119–123 (2007).
Tesselaar, M. E. et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J. Thromb. Haemost. 5, 520–527 (2007).
Toth, B. et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb. Haemost. 100, 663–669 (2008).
Thomas, G. M. et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J. Exp. Med. 206, 1913–1927 (2009).
Tilley, R. E., Holscher, T., Belani, R., Nieva, J. & Mackman, N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb. Res. 122, 604–609 (2008).
Nachman, R. L. & Rafii, S. Platelets, petechiae, and preservation of the vascular wall. N. Engl. J. Med. 359, 1261–1270 (2008).
Von Hundelshausen, P. & Weber, C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ. Res. 100, 27–40 (2007).
Popivanova, B. K. et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 69, 7884–7892 (2009).
Jung, D.-W. et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int. J. Cancer 127, 332–344 (2010).
Keeley, E. C., Mehrad, B., Strieter, R. M., George, F. V. W. & George, K. in Adv. Cancer Res. 91–111 (Academic Press, 2010).
Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. 4, 923–928 (1998).
Geiger, T. R. & Peeper, D. S. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res. 67, 6221–6229 (2007).
Bronckaers, A., Gago, F., Balzarini, J. & Liekens, S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med. Res. Rev. 29, 903–953 (2009).
Ikushima, H. & Miyazono, K. TGFβ signalling: a complex web in cancer progression. Nature Rev. Cancer 10, 415–424 (2010).
Medina, V. A. & Rivera, E. S. Histamine receptors and cancer pharmacology. Br. J. Pharmacol. 161, 755–767 (2010).
Falcon, B. L. et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 175, 2159–2170 (2009).
Ho, M.-Y. et al. Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression. Cancer Science 101, 2411–2416 (2010).
Melnikova, V. & Bar-Eli, M. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev. 26, 359–371 (2007).
Visentin, B. et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9, 225–238 (2006).
David, M. et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE 5, e9741 (2010).
Amirkhosravi, A. et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin. Thromb. Hemost. 33, 643–652 (2007).
B.F.H. is supported by grants from the US National Institutes of Health (NIH) (CA 112287), the California Breast Cancer Research Program (12NB0176 and 13NB0180) and the US Department of Defense (W81XWH-08-1-0468). L.J.G. is supported by a trainee scholarship from NIH grant 5TL1RR025772-03.
The authors declare no competing financial interests.
- Blood perfusion model
Parallel plate flow chamber system in which adhesive interactions between blood-borne tumour cells, blood cells, platelets and endothelial cells are monitored and measured by video microscopy.
- Disseminated intravascular coagulation
Pathological activation of coagulation (blood clotting) mechanisms that leads to the formation of small blood clots in blood vessels throughout the body.
- Endothelial retraction
Disruption of adherens junctions of endothelial cells creates gaps in the endothelial monolayer and increases vascular permeability while exposing the matrix proteins of the basement membrane.
Carbohydrate-linked lipids and proteins, which include receptors and ligands that function as cell adhesion molecules.
- Migratory thrombophlebitis
Malignancy-associated hypercoagulable state leading to spontaneous platelet-rich clots in veins anywhere in the body that dynamically form, resolve and reappear.
- Paraneoplastic disease
Disease induced as a result of tumour burden; generally caused by the release of tumour-derived hormones, peptides or cytokines, or by the misguided destruction of normal tissue by immune cells targeted against malignant cells.
- Pulmonary embolism
Blockage of the main artery of the lung or one of its branches by a platelet-rich clot that originated in the venous circulation and dislodged from where it initially formed.
- Shear stress
The velocity of flowing blood is highest in the centre of vessels and decreases towards the vessel wall, resulting in differential flow that generates a shearing force.
- Thromboembolic disease
Condition caused by travelling blood clots or emboli that occlude blood vessels; commonly manifesting as deep vein thrombosis or pulmonary embolism in cancer patients.
- Weibel–Palade bodies
Secretory granules of endothelial cells that particularly store and secrete multimerized von Willebrand factor, and which translocate P-selectin to the membrane surface on cell activation.
About this article
Cite this article
Gay, L., Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 11, 123–134 (2011). https://doi.org/10.1038/nrc3004
This article is cited by
Molecular Cancer (2023)
Signal Transduction and Targeted Therapy (2023)
Acta Pharmacologica Sinica (2023)
Nature Reviews Clinical Oncology (2023)
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis
Journal of Experimental & Clinical Cancer Research (2023)